MAB Mabion S.A.

GPW · PL · Healthcare · Biotechnology · mabion.eu

7.850PLN+0.64%Mkt Cap: 32.13M $P/E: —3d ago

Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell lin…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap32.13M USD

Enterprise Value38.82M USD

Revenue (TTM)4.46M USD

Gross Profit-4.41M USD

Net Income (TTM)-15.86M USD

Revenue/Share1.09 PLN

Last Price7.850 PLN

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees199

CountryPL

SectorHealthcare

IndustryBiotechnology

ISINPLMBION00016

Valuation

P/E (Trailing)—

P/E (Forward)-3.51

PEG—

EV/EBITDA-5.18

EV/Revenue8.70

P/S7.16

P/B5.22

EPS (TTM)-3.50

EPS (Forward)-2.22

52W Range

6.70035% of range10.00

52W High10.00 PLN

52W Low6.700 PLN

Profitability

Gross Margin-110.52%

Oper. Margin-180.11%

EBITDA Margin-167.88%

Profit Margin-397.37%

ROE-128.23%

ROA-56.70%

Growth

Revenue Growth0.10%

Earnings Growth—

Cash Flow & Leverage

Operating CF-10.53M USD

CapEx (TTM)225.91K USD

FCF Margin-98.94%

FCF Yield-13.74%

Net Debt6.75M USD

Net Debt/EBITDA-0.90

Balance Sheet

Debt/Equity0.26

Current Ratio0.32

Quick Ratio0.16

Book Value/Sh1.49 PLN

Cash/Share0.36 PLN

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 PLN

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.16.16M

Float11.48M

Insiders28.98%

Institutions0.00%

Technical

SMA 507.681 (+2.2%)

SMA 2007.849 (+0.0%)

Beta0.38

S&P 52W Chg13.94%

Avg Vol (30d)36.35K

Avg Vol (10d)23.88K

Technical Indicators

RSI (14)52.9

MACD0.0227

MACD Signal0.0313

MACD Hist.-0.0086

BB Upper8.079 PLN

BB Middle7.833 PLN

BB Lower7.588 PLN

BB Width6.27%

ATR (14)0.2377 PLN

Vol Ratio (20d)0.39x